US LNG exports surge but will buyers in China turn up?
WEXFORD, Pa. - Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP), a small-cap biotech company with a market capitalization of $37.6 million, announced Tuesday it has extinguished its convertible note with YA II PN, Ltd (Yorkville), clearing all outstanding debt obligations to the lender.
The convertible note, which was dated January 16, 2025, has been fully settled according to the company’s statement. This debt clearance comes as Coeptis positions itself for potential expansion into cryptocurrency operations. According to InvestingPro data, the company operates with a moderate debt level, though its current ratio of 0.82 indicates some liquidity challenges.
"The extinguishment of these outstanding debt obligations strengthens the Company’s capital structure and positions us well to pursue our long-term goals," said David Mehalick, CEO of Coeptis Therapeutics Holdings, in the press release. The company’s stock has shown remarkable performance, with a year-to-date return of nearly 95%.
The company noted that eliminating this debt creates a more streamlined capital structure that could facilitate its proposed strategic addition of cryptocurrency-related operations.
Coeptis Therapeutics describes itself as a next-generation technology and biopharmaceutical company with divisions focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. The company’s therapeutic portfolio includes assets licensed from Deverra Therapeutics and technology developed in collaboration with the University of Pittsburgh and the Karolinska Institute.
The company has recently established a Technology Division focused on operational enhancements through advanced technologies, including AI-powered marketing software and robotic process automation tools.
The information in this article is based on a press release statement from Coeptis Therapeutics Holdings.
In other recent news, SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings Inc., has entered into a licensing agreement with Monarch Therapeutics Inc. This collaboration aims to further develop and commercialize the Snap-Car NK cell therapy platform for oncology treatments. The partnership is designed to enhance the precision and flexibility of cancer therapies by utilizing Monarch’s small molecule adaptor technology. This technology is expected to address challenges such as tumor heterogeneity and antigen escape, potentially leading to more effective treatments for patients with difficult-to-treat cancers. These developments reflect ongoing efforts to improve therapeutic approaches in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.